- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05227053
STOPP AF Första studien efter godkännande
STOP AF First Post-Approval Study, ett tillägg till Cryo Global Registry
The STOP AF First PAS is a prospective, global, multi-center, observational trial.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The STOP AF First Post Approval Study (PAS) is a sub-study to the Cryo Global Registry. The STOP AF First PAS is a prospective, global, multi-center, observational trial. The purpose of the study is to describe long-term clinical performance and safety data in the recurrent symptomatic paroxysmal AF population treated with Arctic Front™ and Freezor™ MAX Families of cardiac cryoablation catheters (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System) as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy. This PAS is a condition of the pre-market approval order (P100010/S110) by the U.S. Food and Drug Administration.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Alaska
-
Anchorage, Alaska, Förenta staterna, 99508
- Alaska Heart Institute
-
-
Connecticut
-
Stamford, Connecticut, Förenta staterna, 06905-5522
- Cardiology Associates of Fairfield County
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Clearwater, Florida, Förenta staterna, 33756
- BayCare Medical Group Cardiology
-
Davie, Florida, Förenta staterna, 33328
- Heart Rhythm Solutions
-
-
Iowa
-
West Des Moines, Iowa, Förenta staterna, 50266
- Iowa Heart
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Förenta staterna, 02747
- Southcoast Health System
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48202-2608
- Henry Ford Heart & Vascular
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45219
- The Lindner Research Center
-
-
Tennessee
-
Germantown, Tennessee, Förenta staterna, 38138
- Stern Cardiovascular Foundation
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75231
- Texas Health Research and Education Institute
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a recommendation for a pulmonary vein ablation with the Arctic Front™ cardiac cryoablation catheter System.
Beskrivning
Inclusion Criteria:
- Subject has been diagnosed with symptomatic paroxysmal AF
- Subject is ≥ 18 years of age or minimum age as required by local regulations
- Planned pulmonary vein isolation (PVI) procedure using the commercially available Arctic Front™ cardiac cryoablation catheter System.
- Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements
Exclusion Criteria:
History of AF treatment with a class I or III antiarrhythmic drug, including sotalol, with the intention to prevent an AF recurrence1
. Subjects under the following conditions may be included in the study:
-
Temporary treatment with a class I or III AAD (treatment at a therapeutic dose for a period of <4 weeks prior to the index PVI procedure)
-
Recent treatment with a class I or III AAD (within 6 months of the index PVI procedure) at a dose below therapeutic threshold according to the AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation
-
A subject who has received a chemical cardioversion may be included in the study. This includes a chemical cardioversion prior to enrollment and between enrollment and ablation.
- Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL)
- Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager
- Subject with exclusion criteria required by local law
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)
Tidsram: 36 months
|
Estimate the 36-month freedom from Atrial Fibrillation (AF) /atrial flutter (AFL) /Atrial Tachycardia (AT) recurrence using the Arctic Front™ cardiac cryoablation catheter System. |
36 months
|
|
Freedom from Primary Safety Events
Tidsram: 12 months
|
Estimate primary safety Adverse Event (AE) rates for cryoablation using the Arctic Front™ cardiac cryoablation catheter System through 12-months. |
12 months
|
Samarbetspartners och utredare
Utredare
- Studierektor: Khaldoun Tarakji, MD, Medtronic CAS Chief Medical Officer
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- STOP AF First PAS
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .